Abstract
Many important clinical questions concerning primary Sjogren’s syndrome (pSS) remain, that can only be adequately addressed by prospective cohorts. Thus, a better knowledge of the clinical outcome, the course of disease activity and the risk factors of lymphoma requires the setting up of cohorts with biobanks. The homogeneous collection of clinical data, disease activity, patient-related outcome, and biological samples, including DNA, RNA and serum, is definitively mandatory to determine new biological prognostic factors and identify disease activity markers. Three large prospective cohorts have already started to enroll patients with pSS. This will be highly invaluable for scientists and clinicians to gain a better insight into the pathogenesis of pSS, as well as to identify prognostic markers and new therapeutic targets.
Keywords: Sjogren’s syndrome, prospective, cohort, disease activity, marker, clinical outcome, pathogenesis, therapeutic targets, clinical data, dryness symptoms, clinical disease, physical fatigue, prognostic factors, Sjogren’s International Collaborative Clinical Alliance (SICCA), clinical data.
Current Pharmaceutical Biotechnology
Title:Primary Sjogren’s Syndrome: Time for Prospective Cohorts
Volume: 13 Issue: 10
Author(s): Jacques-Eric Gottenberg and Xavier Mariette
Affiliation:
Keywords: Sjogren’s syndrome, prospective, cohort, disease activity, marker, clinical outcome, pathogenesis, therapeutic targets, clinical data, dryness symptoms, clinical disease, physical fatigue, prognostic factors, Sjogren’s International Collaborative Clinical Alliance (SICCA), clinical data.
Abstract: Many important clinical questions concerning primary Sjogren’s syndrome (pSS) remain, that can only be adequately addressed by prospective cohorts. Thus, a better knowledge of the clinical outcome, the course of disease activity and the risk factors of lymphoma requires the setting up of cohorts with biobanks. The homogeneous collection of clinical data, disease activity, patient-related outcome, and biological samples, including DNA, RNA and serum, is definitively mandatory to determine new biological prognostic factors and identify disease activity markers. Three large prospective cohorts have already started to enroll patients with pSS. This will be highly invaluable for scientists and clinicians to gain a better insight into the pathogenesis of pSS, as well as to identify prognostic markers and new therapeutic targets.
Export Options
About this article
Cite this article as:
Gottenberg Jacques-Eric and Mariette Xavier, Primary Sjogren’s Syndrome: Time for Prospective Cohorts, Current Pharmaceutical Biotechnology 2012; 13 (10) . https://dx.doi.org/10.2174/138920112802273128
DOI https://dx.doi.org/10.2174/138920112802273128 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of CXCR2/CXCR2 Ligands in Acute Lung Injury
Current Drug Targets - Inflammation & Allergy Statins in Stable Angina Pectoris
Current Pharmaceutical Design A Brief Review of the Computational Identification of Antifreeze Protein
Current Organic Chemistry Towards an Evidence-based Model of Aging
Current Aging Science Therapeutic Targeting of B Lymphocyte Stimulator (BLyS) in the Rheumatic Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Patent Selections
Recent Patents on Drug Delivery & Formulation Role of Matrix Metalloproteinases in Animal Models of Ischemic Stroke
Current Vascular Pharmacology Nanoparticle Targeting to Inflamed Tissues of the Gastrointestinal Tract
Current Drug Delivery Gender Specific Aspects of Cell Death in the Cardiovascular System
Current Pharmaceutical Design Anesthetic Cardioprotection in Clinical Practice From Proof-of-Concept to Clinical Applications
Current Pharmaceutical Design Oleanolic Acid and Related Triterpenoids from Olives on Vascular Function: Molecular Mechanisms and Therapeutic Perspectives
Current Medicinal Chemistry Synthesis and Biological Evaluations of Cytotoxic and Antiangiogenic Triterpenoids-Jacaranone Conjugates
Medicinal Chemistry Hemichannels in the Neurovascular Unit and White Matter Under Normal and Inflamed Conditions
CNS & Neurological Disorders - Drug Targets The Blood-Brain Barrier in NeuroAIDS
Current HIV Research Prospects of Molecularly-Targeted Therapies for Cervical Cancer Treatment
Current Drug Targets The Role of Intracellular 35-Cyclic Adenosine Monophosphate (cAMP) in Atherosclerosis
Current Vascular Pharmacology Co-delivery Strategies Based on Multifunctional Nanocarriers for Cancer Therapy
Current Drug Metabolism Mechanisms for Targeted Delivery of Nanoparticles in Cancer
Current Pharmaceutical Design Ocular Inflammatory Diseases: Molecular Pathogenesis and Immunotherapy
Current Molecular Medicine Current Strategies in TB Immunotherapy
Current Molecular Medicine